10-Q: Arvinas Reports Reduced Losses, Advances Pipeline, Shifts Vepdegestrant Strategy

Arvinas, Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, driven by collaboration revenue and cost-saving measures, while advancing its PROTAC degrader pipeline and announcing a strategic shift for vepdegestrant commercialization.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $13.4 million from $153.8 million in the prior year period.
• Revenue for the nine months increased by $48.9 million to $253.1 million, primarily due to a $157.9 million increase from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer and a $20.0 million development milestone from Novartis.
• Research and development expenses decreased by $40.8 million to $224.1 million for the nine months, reflecting reduced external and personnel costs.
• General and administrative expenses decreased by $58.4 million to $72.9 million for the nine months, largely due to a $43.4 million loss on lease termination in August 2024 and reduced personnel costs.
• Cash, cash equivalents, and marketable securities totaled $787.6 million as of September 30, 2025, expected to fund operations into the second half of 2028.
• Positive topline Phase 3 VERITAC-2 clinical trial results for vepdegestrant in ESR1-mutated breast cancer patients, showing a 43% reduction in disease progression or death risk compared to fulvestrant (HR=0.57; P<0.001).
• A New Drug Application (NDA) for vepdegestrant was submitted to the FDA in Q2 2025 and accepted in Q3 2025, with a PDUFA action date of June 5, 2026.
• Arvinas and Pfizer agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant, leading to a decision not to build out Arvinas's own commercial infrastructure.
• Presented positive Phase 1 data for ARV-102 (LRRK2 degrader for Parkinson's Disease) at the 2025 International Congress of Parkinson's Disease and Movement Disorders, demonstrating substantial LRRK2 reduction in CSF and a promising safety profile.
• Initiated enrollment in a Phase 1 clinical trial for ARV-806 (KRAS G12D degrader for mutated cancers) in Q2 2025, following IND approval from the FDA.
• Preclinical data for ARV-393 (BCL6 degrader for NHL) showed strong synergistic antitumor activity in combination with standard of care and investigational agents, supporting broad utility across NHL subtypes.
• Implemented two workforce reductions in Q2 and Q3 2025 (approximately 33% and an additional 15%, respectively) to streamline operations and achieve an expected $100.0 million in annual operating cost savings.
• The board of directors authorized a $100.0 million share repurchase program in September 2025, with $20.2 million utilized to repurchase 2,560,030 shares by September 30, 2025.

Sentiment

Score: 7

Explanation: The company reported significantly reduced net losses and positive Phase 3 data for vepdegestrant, leading to an NDA acceptance. Pipeline assets ARV-102, ARV-393, and ARV-806 also show promising preclinical or early clinical progress. Strategic workforce reductions and a strong cash runway into H2 2028 demonstrate financial prudence. However, the decision to seek a third party for vepdegestrant commercialization, ongoing need for substantial future funding, and risks related to FDA disruptions temper the overall positive sentiment.

Positives

• Net loss significantly reduced to $13.4 million for the nine months ended September 30, 2025, compared to $153.8 million in the prior year.
• Revenue increased by $48.9 million for the nine months, driven by collaboration agreements and a development milestone payment.
• Vepdegestrant's Phase 3 VERITAC-2 trial met its primary endpoint in ESR1m patients, showing a statistically significant 43% reduction in disease progression or death risk (HR=0.57; P<0.001).
• The FDA accepted the New Drug Application (NDA) for vepdegestrant, setting a PDUFA action date of June 5, 2026.
• ARV-102 demonstrated substantial LRRK2 reduction in cerebral spinal fluid (CSF) and a promising safety/tolerability profile in Phase 1 trials for Parkinson's Disease.
• Preclinical data for ARV-393 showed strong synergistic antitumor activity and broad utility across non-Hodgkin Lymphoma subtypes.
• ARV-806 initiated Phase 1 clinical trials for KRAS G12D mutated cancers, with preclinical data suggesting potential as a best-in-class therapy.
• The company maintains a strong liquidity position with $787.6 million in cash, cash equivalents, and marketable securities, projected to fund operations into the second half of 2028.
• Cost-saving measures, including workforce reductions, are expected to yield $100.0 million in annual operating cost savings.

Negatives

• Vepdegestrant's VERITAC-2 trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population (HR=0.83; P=0.07).
• The decision to jointly select a third party for vepdegestrant commercialization indicates Arvinas will not build its own commercial infrastructure for this lead asset, potentially limiting future direct revenue streams.
• Net cash used in operating activities increased by $68.2 million for the nine months ended September 30, 2025, primarily due to a decrease in deferred revenue.
• Net cash used in financing activities shifted to negative, primarily due to share repurchases and decreased proceeds from stock option exercises.
• The company continues to incur significant operating losses and expects to do so for the foreseeable future, despite cost-saving measures.

Risks

• Cost savings plan and associated workforce reductions may not achieve anticipated savings, could result in higher than expected costs, and may disrupt business operations, including clinical trials and commercialization.
• Workforce reductions could lead to unanticipated attrition, disruptions in day-to-day operations, and harm the ability to attract and retain qualified management, scientific, clinical, manufacturing, and sales and marketing personnel.
• Disruptions at the U.S. Food and Drug Administration (FDA) and other government agencies due to funding cuts, personnel losses (e.g., 3,500 FDA employees affected by RIF), regulatory reform, or government shutdowns could delay guidance, review, and approval of product candidates.
• A prolonged government shutdown, such as the one starting October 1, 2025, could significantly impact the FDA's ability to process regulatory submissions and the company's access to public markets for capital.
• The share repurchase program is not an obligation, and the company may purchase only a limited number of shares or reduce/eliminate the program, which could adversely affect the market price of common stock.
• The company has incurred significant losses since inception and expects to continue incurring losses for at least the next several years, with profitability highly uncertain.
• Substantial additional funding will be needed to continue operations, and inability to raise capital on acceptable terms could force delays, reductions, or termination of research and development programs or commercialization efforts.
• Resource allocation decisions may cause the company to forego or delay pursuit of opportunities with greater commercial potential.
• Future success depends on the ability to retain key employees, consultants, and advisors, and to manage the search for and appointment of a new chief executive officer, with leadership changes posing inherent risks and potential disruptions.
• Changes in tax laws or their implementation/interpretation (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may adversely affect the business and financial condition, including effective tax rate, liabilities, and cash obligations.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances preclinical and clinical development of its product candidates. It anticipates substantial increases in expenses related to ongoing and planned clinical trials, progression of preclinical programs, and expansion of its PROTAC Discovery Engine. The company believes its current cash, cash equivalents, and marketable securities of $787.6 million will fund planned operating expenses and capital expenditure requirements into the second half of 2028. Future capital requirements will depend on various factors, including clinical trial progress, regulatory outcomes, commercialization costs, and intellectual property protection. The company will need substantial additional funding and may seek it through equity offerings, debt financings, collaborations, or licensing arrangements.

Management Comments

• We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities.
• We believe our LRRK2 degraders are particularly well positioned to be evaluated in two diseases where there are no disease modifying therapies available: Parkinson's Disease and progressive supranuclear palsy.
• We believe these data presented at MDS highlight the potential PROTAC-mediated LRRK2 degradation, which supports the development of ARV-102 in ongoing studies of patients with PD, and potential future studies of patients with PSP.
• We believe that PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6 and that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with NHL.
• We believe the totality of our preclinical data for ARV-393 provides a compelling rationale to evaluate ARV-393 in combination with bi-specifics, oral pathway inhibitors, and potentially other standards of care, in the larger diffuse large B-cell lymphoma indication.
• We believe ARV-806 has the potential to be a best-in-class therapy for kristen rat sarcoma G12D mutated cancers.
• We believe that, based on these strong data from VERITAC-2, vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1m setting.
• While we continue to believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1m setting, given our and Pfizer's decision to remove the two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan as noted above, we have determined that it is no longer viable for us to build out our commercial infrastructure as we had previously planned.

Industry Context

Arvinas operates in the highly competitive biopharmaceutical industry, specializing in PROTAC targeted protein degraders, a novel therapeutic modality. The positive Phase 3 results for vepdegestrant in ESR1m breast cancer position it as a potential best-in-class monotherapy, a significant achievement in a crowded oncology market. The strategic decision to seek a third party for vepdegestrant commercialization, rather than building internal infrastructure, reflects a focus on core R&D and a pragmatic approach to market entry, potentially leveraging established commercial networks. The advancement of ARV-102 for neurodegenerative disorders and ARV-806 for KRAS G12D mutated cancers addresses areas with high unmet medical needs, where traditional small molecule inhibitors have faced limitations. The company's pipeline progress, coupled with cost optimization, suggests a strategic effort to enhance value in a capital-intensive sector.

Comparison to Industry Standards

• Vepdegestrant's 43% reduction in disease progression or death risk (HR=0.57) in ESR1m breast cancer patients compared to fulvestrant in the VERITAC-2 trial is a strong clinical outcome, potentially positioning it favorably against other ER degraders or selective estrogen receptor down-regulators (SERDs) in development or on the market for this indication.
• ARV-806's preclinical data showing more than 25-fold greater potency in reducing cancer cell proliferation and more than 40-fold higher potency in degrading KRAS G12D protein compared to a leading clinical-stage G12D degrader suggests a potentially superior profile in the competitive KRAS inhibitor/degrader space, which includes companies like Amgen (Lumakras) and Mirati Therapeutics (Krazati) for KRAS G12C, and others developing G12D specific agents.
• The LRRK2 degradation observed with ARV-102 in CSF is a critical indicator of brain penetration and target engagement, which is a key challenge in developing therapies for neurodegenerative diseases like Parkinson's, where many compounds fail to adequately cross the blood-brain barrier.
• The company's cash runway into the second half of 2028, following significant R&D investment and workforce reductions, is a reasonable timeframe for a clinical-stage biotechnology company, providing stability for ongoing trials and pipeline development.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• The company and Bayer CropScience LP formed Oerth Bio LLC, a joint venture in which the company held 43.3% ownership interest as of September 30, 2025. The company also provides Oerth Bio with compensated research, development, and administrative services, which were immaterial during the reporting period.

Stakeholder Impact

• **Shareholders**: Positive Phase 3 results for vepdegestrant and pipeline progress could increase shareholder value. The share repurchase program may also benefit shareholders. However, the strategic shift for vepdegestrant commercialization and ongoing need for future funding introduce uncertainty.
• **Employees**: Workforce reductions (totaling approximately 48%) will significantly impact employees, leading to job losses and potential morale issues, but are intended to streamline operations and ensure long-term viability. Remaining employees may face increased workloads and uncertainty.
• **Customers (Future Patients)**: Positive clinical trial data for vepdegestrant and other pipeline candidates offer hope for new therapeutic options for debilitating diseases like breast cancer, Parkinson's, and various cancers.
• **Collaboration Partners (Pfizer, Novartis)**: The collaboration with Pfizer for vepdegestrant continues, with a joint decision to seek a third party for commercialization. Novartis is advancing luxdegalutamide (ARV-766) in Phase 2 trials, indicating continued progress for out-licensed assets.
• **Creditors**: The company's strong cash position and projected runway into H2 2028 provide confidence in its ability to meet short-term obligations, despite ongoing operating losses.

Next Steps

• Present initial data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's Disease in 2026.
• Initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy (PSP) in the first half of 2026, pending regulatory feedback.
• Share preclinical data for ARV-393 in combination with glofitamab at the American Society of Hematology 2025 annual meeting in Q4 2025.
• Initiate enrollment in a Phase 1 clinical trial of ARV-393 in combination with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) in 2026.
• Share updated clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with non-Hodgkin Lymphoma at a medical congress in 2026.
• Anticipate sharing initial clinical data from the Phase 1 clinical trial of ARV-806 in patients with advanced solid tumors harboring KRAS G12D mutations in 2026.
• Present new preclinical data for ARV-027 at the International Congress of the World Muscle Society in Q4 2025.
• Expect to initiate a first-in-human Phase 1 clinical trial for ARV-027 in healthy volunteers in 2026, pending regulatory feedback.
• Present preclinical data for ARV-6723 at the Society for Immunotherapy of Cancer annual meeting in Q4 2025.
• Plan to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in 2026, pending regulatory feedback.
• Continue market preparations for vepdegestrant in advance of the PDUFA action date of June 5, 2026.
• Jointly select a third party with Pfizer for the commercialization and potential future development of vepdegestrant.
• Complete the additional 15% workforce reduction by the first quarter of 2026.
• Continue the search for and appointment of a new chief executive officer.

Key Dates

Recommendation

The filing presents a mixed but generally positive outlook. The significant reduction in net loss and the positive Phase 3 VERITAC-2 results for vepdegestrant, leading to an FDA NDA acceptance, are strong positives. This indicates clinical validation and a clear path to potential market entry for a key asset. The progress across other pipeline candidates (ARV-102, ARV-393, ARV-806) further strengthens the long-term potential. However, the strategic decision to outsource vepdegestrant commercialization, while potentially efficient, signals a departure from building an internal commercial engine for a lead product, which could cap upside from direct sales. The company also faces ongoing risks from workforce reductions, potential FDA delays, and the need for substantial future funding. While the cash runway is solid for the near term, the long-term profitability remains uncertain. Given the significant clinical progress balanced by strategic shifts and inherent biotech risks, a 'hold' recommendation is appropriate, allowing investors to monitor the vepdegestrant commercialization strategy, further pipeline data, and the impact of cost-saving measures.

Keywords

PROTAC, Protein Degradation, Vepdegestrant, ARV-471, Breast Cancer, ESR1m, NDA, FDA, ARV-102, Parkinson's Disease, LRRK2, ARV-393, Non-Hodgkin Lymphoma, BCL6, ARV-806, KRAS G12D, Oncology, Neurodegenerative, Biotechnology, Clinical Trials, SEC Filing, Financial Results, Workforce Reduction, Share Repurchase